According to the report, the Europe Next-Generation Antibody Therapeutics Market size is valued at USD 1.10 billion in 2021. It is expected to grow at a CAGR of 14.2% to reach USD 2.13 billion by 2026. It captures 25% of the global market.
Increasing funds and investments for improving the healthcare sector during the time of COVID-19 is one major factor impelling the market growth. Escalating the patient population visiting the hospitals regularly with a surge in chronic disorders fosters market demand. The introduction of the latest technologies leading to more effective antibody therapies and product innovations augments market growth. Rising government support in developing life science research infrastructure and developing drugs is expected to drive the market demand. Biosimilar antibodies and engineered antibodies have rapid growth in the next-generation antibody therapeutics and are projected to fuel market growth.
However, the cost associated with the treatment procedures for antibodies is prohibitive, impeding market growth. Strict government measures and time taking approval process are restraining the next-generation antibody therapeutics market growth in Europe. Increasing importance for old generation drug therapies and less knowledge about the antibodies and the related treatments among the people living in rural areas obstruct the market demand.
This research report on the Europe Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories:
By Therapeutics:
By Technology:
By Country:
Based on the region, Europe is the second-largest market. It is expected to remain so by bridging North America's deficit towards the tail end of the forecast period.
The UK is expected to hold the largest share of the market. Increasing demand for superior healthcare services is driving the market demand. The escalating number of pharma, biotechnology, and biopharma companies are mainly investing in the advancements of next-gen therapeutic antibodies is flourishing the market growth. Growing utilization of antibody-drug conjugate (ADC) is presently leading the market with significant demand positively impacting the market. Germany is followed after the UK and is the second leading with market share. Increasing developments in technology about the usage of monoclonal antibody is anticipated to drive the market growth. France, Spain, Russia, and the Rest of Europe are considered to have a substantial market in the upcoming years.
Promising Companies dominating the European Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technology
5.1.1 Introduction
5.1.2 Antibody-Drug Conjugates (ADCs)
5.1.3 Bispecific Antibodies (BsAbs)
5.1.4 Fc Engineered Antibodies
5.1.5 Antibody Fragments and Antibody-like Proteins
5.1.6 Biosimilar Antibody Products
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 Oncology
5.2.3 Autoimmune/Inflammatory Diseases
5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.5 Market Attractiveness Analysis, By Therapeutic Application
5.2.6 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technology
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technology
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technology
6.1.5.3 By Therapeutic Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Seattle Genetics
8.3 Takeda
8.4 Dyax Corp.
8.5 Immunogen
8.6 Amgen, Inc.
8.7 Biogen
8.8 Kyowa Hakko Kirin Co., Ltd.
8.9 AstraZeneca
8.10 Pfizer, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
